FP
ABBV icon

Foundry Partners’s AbbVie ABBV Stock Holding History

Foundry Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$20.4M Sell
97,354
-5,610
-5% -$1.09M 1.08% 24
2024
Q4 		$18.3M Sell
102,964
-818
-0.8% -$150K 0.92% 30
2024
Q3 		$20.5M Sell
103,782
-698
-0.7% -$130K 1.01% 23
2024
Q2 		$17.9M Buy
104,480
+101,700
+3,658% +$16.8M 0.96% 26
2024
Q1 		$506K Sell
2,780
-515
-16% -$88.8K 0.03% 224
2023
Q4 		$511K Hold
3,295
– – 0.03% 228
2023
Q3 		$491K Sell
3,295
-555
-14% -$81.5K 0.03% 226
2023
Q2 		$519K Buy
3,850
+625
+19% +$91.7K 0.03% 239
2023
Q1 		$514K Hold
3,225
– – 0.03% 237
2022
Q4 		$521K Hold
3,225
– – 0.03% 227
2022
Q3 		$433K Buy
3,225
+725
+29% +$104K 0.03% 248
2022
Q2 		$383K Sell
2,500
-3,035
-55% -$464K 0.02% 250
2022
Q1 		$897K Hold
5,535
– – 0.05% 237
2021
Q4 		$749K Buy
5,535
+329
+6% +$38.9K 0.03% 256
2021
Q3 		$562K Sell
5,206
-637
-11% -$72.8K 0.02% 280
2021
Q2 		$658K Buy
5,843
+150
+3% +$16.9K 0.02% 296
2021
Q1 		$616K Hold
5,693
– – 0.02% 368
2020
Q4 		$610K Sell
5,693
-119,423
-95% -$11.5M 0.02% 349
2020
Q3 		$11M Buy
125,116
+122,487
+4,659% +$11.5M 0.53% 62
2020
Q2 		$258K Buy
+2,629
New +$231K 0.01% 370
2015
Q1 		– Sell
-188,170
Closed -$12.3M – 262
2014
Q4 		$12.3M Buy
188,170
+24,285
+15% +$1.53M 1.01% 30
2014
Q3 		$9.47M Sell
163,885
-22,540
-12% -$1.25M 0.88% 37
2014
Q2 		$10.5M Buy
+186,425
New +$9.78M 0.98% 25

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Foundry Partners's ABBV Position: Q1 2025 in Review

Foundry Partners reduced its AbbVie (ABBV) stake by 5.4% in Q1 2025, selling an estimated $1.09M and leaving 97,354 shares worth $20.4M. The position accounts for 1.08% of the portfolio, ranked #24.

Foundry Partners first reported a position in ABBV in Q2 2014 and has held it in 23 quarters since. The position peaked at $20.5M in Q3 2024. 3,819 funds tracked by Wall St. Rank hold ABBV as of Q1 2025.

  • Foundry Partners held 97,354 shares of AbbVie worth $20.4M as of Q1 2025.
  • Foundry Partners sold 5,610 AbbVie shares in Q1 2025, an estimated $1.09M.
  • AbbVie made up 1.08% of Foundry Partners's portfolio in Q1 2025, its #24 holding.
  • Foundry Partners first reported a position in AbbVie in Q2 2014 and has held it in 23 quarters since.
  • Foundry Partners's AbbVie position peaked at $20.5M in Q3 2024.
  • 3,819 funds tracked by Wall St. Rank held AbbVie as of Q1 2025.

Based on Foundry Partners's 13F filing for Q1 2025, filed 5 May 2025.